Recursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event

We recently published 10 Stocks Stealing Today’s Spotlight; 5 on All-Time Highs. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Wednesday.

Recursion Pharmaceuticals extended its winning streak to a third straight day on Wednesday, jumping 15.28 percent to close at $6.79 apiece as investors loaded portfolios following a recently concluded major AI conference in Dubai.

On Wednesday, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) cofounder and CEO Chris Gibson spoke at the event, where he tackled how AI was shaping the company’s future direction, specifically, its approach to generating data, automating experiments, and using AI and machine learning for its discoveries.

Additionally, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Research and Development Officer Najat Khan is expected to take part in an upcoming virtual summit, “The State of AI in Drug Discovery” on October 29, where he and fellow Boltz-2 developers from the Massachusetts Institute of Technology will talk about the democratization of small molecule drug discovery.

Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but at speeds up to 1000x faster in standard benchmarks.

While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.